Sanner acquisition strengthens company's leadership in effervescent packaging market
The purchase contract was signed on May 18: Sanner GmbH acquires Jaco S.A. (from left to right: Ralf Tiemann, Managing Director Sanner Kunshan China; Jürgen Sanner, Shareholder Sanner; Sibylle Rippmann, former owner of Jaco SA; Tharcisse Decker, Managing Director Jaco SA; Dirk Mähr, Managing Director Sanner GmbH)
Acquisition of Jaco enables Sanner to operate as a system supplier.
Sanner has acquired Plastina Holding AG, the parent company of Jaco S.A., based in Kirchheim, Germany. Through the merger, Sanner now advances to the global market leader for effervescent packaging.
Sanner is known as market leader for desiccant packaging in the global pharmaceutical and healthcare sector. Jaco S.A. is a leading manufacturer of printed and unprinted plastic tubes for effervescent tablets. "Our product portfolios complement each other ideally," says Dirk Mähr, Managing Director of Sanner. "As a result of the merger, we have significantly strengthened our market position and have become the world market leader for effervescent packaging.” In 2016, Sanner generated annual sales of 63.7 million euro, whereas Jaco achieved around 13 million euro.
"Together, we offer our customers one of the most comprehensive ranges of tubes and closures, combined with numerous decoration possibilities. This allows us to operate as a system supplier in the future,” says Tharcisse Decker, Managing Director of Jaco. “Apart from the strong French and European market, we are now also able to enter new markets such as the Middle East or Africa more effectively,” Dirk Mähr adds. Moreover, Jaco’s experience in printing technology can be used for new products, while Sanner’s competencies in research and development are of great advantage for joint, innovative projects.
The acquisition will have no effect on the employees or the production of both companies. Customers will be served by the sites in Bensheim and Kirchheim. The company name Jaco SA will remain unchanged for the time being. The former owners of Jaco S.A have withdrawn from business. The parties agreed on keeping the purchase price confidential.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.